Xiaowei Xu, MD, PhD
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia PA
Member, Abramson Cancer Center
Associate Vice Chair of Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations
Contact information
Hospital of University of Pennsylvania
Dept. of Pathology and Laboratory Medicine
6 Founders Pavilion
Philadelphia, PA 19104-4283
Dept. of Pathology and Laboratory Medicine
6 Founders Pavilion
Philadelphia, PA 19104-4283
Office: 215-662-6503
Fax: 215-349-5910
Fax: 215-349-5910
Email:
xug@pennmedicine.upenn.edu
xug@pennmedicine.upenn.edu
Education:
MD (Medicine)
Fudan University School of Medicine, Shanghai, China, 1992.
PhD (Pharmacology)
Wake Forest University School of Medicine, Winston-Salem, NC, 1996.
Permanent linkMD (Medicine)
Fudan University School of Medicine, Shanghai, China, 1992.
PhD (Pharmacology)
Wake Forest University School of Medicine, Winston-Salem, NC, 1996.
Description of Research Expertise
Develop gamma delta T cell and extracellular vesicle-based immunotherapies for melanoma and other skin conditionsDescription of Clinical Expertise
Dermatopathology, pigmented lesions and vasculitisSelected Publications
Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X. : Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Sci Adv. 11(3): eadp9009, 2025.Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R,Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Gangadhar TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X,* Guo W*. * indicates co-corresponding authors : Exosomal PD-L1 Mediates Tumor Immunosuppression and is Associated with Patient Response to anti-PD-1 Immunotherapy. Nature 560(7718): 382-386, 2018.
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M*, Xu X*, Guo W*. *Herlyn, Xu and Guo are co-corresponding authors.: PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAFmutant Melanomas. Nature 550(7674): 133-136, 2017
Ma KL, Mitchell TC, Dougher M, Sharon1 CE, Tortorello1 GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura1 JT, Karakousis GC, Xu X.: Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival. Clin Cancer Res 30(21): 4987-4994, 2024.
Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, Luo R, Elder DE, Huang AC, Karakousis G, Miura J, Mitchell T, Schuchter L, Amaravadi R, Flowers A, Mou H, Yi F, Guo W, Ko J, Chen Q, Tian B, Herlyn M, Xu X. : Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine. (92), 104614, 2023
Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, Li L, Huang A, Mitchell TC, Fan Y, June CH, Mills GB, Guo W, Herlyn M, Xu X. : Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. J Immunother Cancer. 9(12): e003339, 2021.
Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, Chen H, Lee RX, Kerestes H, Niu J, Kumar S, Xu W, Zhang J, Wei Z, Martin JS, Liu X, Mills G, Lu Y, Guo W, Weeraratna A, Herlyn M, Wei W, Lee FS, Xu X : Loss of Phd2 Cooperates with BRAFV600E to Drive Melanomagenesis. Nat Commun. 9(1): 5426, 2018
Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, Rebecca VW, Marino GE, Almeida F, Ecker BL, Zabransky DJ, Hüser L, Beer T, Tang HY, Kossenkov A, Herlyn M, Speicher DW, Xu W, Xu X, Jaffee EM, Aguirre-Ghiso JA, Weeraratna AT.: Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature 606(7913): 396-405, 2022.
Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ: TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571(7764): 211-218, 2019.
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton B, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K: Clinical efficacy of a RAF inhibitor requires comprehensive ERK pathway inhibition in BRAF-mutant melanoma. Nature 467(7315): 596-9, 2010